NCT05156268View on ClinicalTrials.gov

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Endometrial Carcinosarcoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.

DRUG

Olaparib

Olaparib will be administered orally at 300 mg every 12 hours.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Maria Rubinstein, Harrison

11553

Maria Rubinstein, Rockville Centre

11725

Maria Rubinstein, Commack

07920

Memorial Sloan Kettering Cancer Center, Basking Ridge

07748

Maria Rubinstein, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER